Study links GLP-1 diabetes drugs like Novo's Ozempic and Eli Lilly's Mounjaro to 12% lower Alzheimer's risk, ahead of Novo's Phase 3 semaglutide Alzheimer's trials.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...